Restrictive measures to control the spread of COVID-19 have adverse effect on continuation of radiotherapy in patients with cancer

The PD-L1 inhibitor avelumab might help some women with gestational trophoblastic tumours avoid combination chemotherapy

Second-look surgery and hyperthermic intraperitoneal chemotherapy may not improve colorectal cancer peritoneal metastases outcomes compared with standard surveillance 

Adding locoregional radiotherapy to chemotherapy may improve overall survival for patients with de novo metastatic nasopharyngeal carcinoma

Pathological near complete response may be more likely with the addition of pazopanib to neoadjuvant chemotherapy for adults and children with advanced soft tissue sarcoma

FOLFIRINOX might be preferable to gemcitabine plus nab-paclitaxel as a first-line regimen for localised pancreatic ductal adenocarcinoma

High-risk operable breast cancer patients who obtain a pathological complete response are more likely to achieve 3-year event-free and distant event-free survival than those who do not

Ipilimumab toxicity in patients with metastatic melanoma may not predict PD-1 inhibitor immune-related adverse events